A Note from Our Team
The REDOSE 2.0 study is separate from REDOSE 1.0, with a different eligibility criteria.
This means that being eligible for REDOSE 1.0 will not make you eligible to partake in REDOSE 2.0, which will be open to both men and women.
You may be eligible for REDOSE 2.0 if you are:
- living with HIV
- on a HIV treatment regimen that contains bictegravir. This is a part of a common combination antiretroviral treatment called biktarvy®
- between the ages of 19 and 50 years, or 60 years and older;
- able to communication in English;
- undetectable (e.g., HIV viral load<40 copies/mL) within the last 14 days;
If you meet all these criteria, you are eligible to be a part of our REDOSE 2.0 study.
What does your participation entail?
In this phase, we are assessing one of the most commonly prescribed HIV regimens in British Columbia, called bictegravir (combined with other HIV medication in a tablet called biktarvy®). The participation would require a two-day visit; the first day is an 8 hours clinic visit, and the second day is a 30-60 minutes visit.
An Honoria of $250 will be provided for your time.
Day 1
Biktarvy dose taken at the beginning of the visit 7 blood draws at set times. Short survey and measures like weight and height Breakfast and lunch provided Free time, activities and a knowledge translation event
Day 2
Final blood draw Honorarium Study Wrap-up
DID YOU KNOW?
8 blood draws (2-3mL of blood per draw) may seem like a lot, but it’s approximately 1-2 tablespoon in total!